📗 Cite This Artifact
Section 128: Advanced Neurotrophic Factor Delivery Systems in CBS/PSP
Section 128: Advanced Neurotrophic Factor Delivery Systems in CBS/PSP
Overview
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 128: Advanced Neurotrophic Factor Delivery Systems in CBS/PSP</th>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT01621581</td>
<td>1</td>
</tr>
<tr>
<td class="label">NCT03709881</td>
<td>1/2</td>
</tr>
<tr>
<td class="label">NCT04135430</td>
<td>2</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Developer</td>
</tr>
<tr>
<td class="label">AAV-CDNF (AAV2-CDNF)</td>
<td>Herantis Pharma</td>
</tr>
<tr>
<td class="label">AAV-CDNF (AAV2.7m8-CDNF)</td>
<td>Herantis Pharma</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT00215850</td>
<td>1</td>
</tr>
<tr>
<td class="label">NCT00976317</td>
<td>2</td>
</tr>
<tr>
<td class="label">NCT01853314</td>
<td>2</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Systemic Delivery</td>
</tr>
<tr>
<td class="label">BBB penetration</td>
<td>Poor</td>
</tr>
<tr>
<td class="label">Distribution</td>
<td>Limited</td>
</tr>
<tr>
<td class="label">Invasive</td>
<td>No</td>
</tr>
<tr>
<td class="label">Repeatable</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Target specificity</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Typical Range</td>
</tr>
<
Section 128: Advanced Neurotrophic Factor Delivery Systems in CBS/PSP
Overview
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 128: Advanced Neurotrophic Factor Delivery Systems in CBS/PSP</th>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT01621581</td>
<td>1</td>
</tr>
<tr>
<td class="label">NCT03709881</td>
<td>1/2</td>
</tr>
<tr>
<td class="label">NCT04135430</td>
<td>2</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Developer</td>
</tr>
<tr>
<td class="label">AAV-CDNF (AAV2-CDNF)</td>
<td>Herantis Pharma</td>
</tr>
<tr>
<td class="label">AAV-CDNF (AAV2.7m8-CDNF)</td>
<td>Herantis Pharma</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT00215850</td>
<td>1</td>
</tr>
<tr>
<td class="label">NCT00976317</td>
<td>2</td>
</tr>
<tr>
<td class="label">NCT01853314</td>
<td>2</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Systemic Delivery</td>
</tr>
<tr>
<td class="label">BBB penetration</td>
<td>Poor</td>
</tr>
<tr>
<td class="label">Distribution</td>
<td>Limited</td>
</tr>
<tr>
<td class="label">Invasive</td>
<td>No</td>
</tr>
<tr>
<td class="label">Repeatable</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Target specificity</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Typical Range</td>
</tr>
<tr>
<td class="label">Infusion rate</td>
<td>0.1-5 μL/min</td>
</tr>
<tr>
<td class="label">Total volume</td>
<td>1-10 mL</td>
</tr>
<tr>
<td class="label">Catheter type</td>
<td>Stepped or reflux-resistant</td>
</tr>
<tr>
<td class="label">Pressure</td>
<td>5-25 mmHg</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>1-4 hours per infusion</td>
</tr>
<tr>
<td class="label">Method</td>
<td>BBB Bypass</td>
</tr>
<tr>
<td class="label">Intraparenchymal</td>
<td>Complete</td>
</tr>
<tr>
<td class="label">Intraventricular</td>
<td>Partial</td>
</tr>
<tr>
<td class="label">Intranasal</td>
<td>Partial</td>
</tr>
<tr>
<td class="label">CED</td>
<td>Complete</td>
</tr>
<tr>
<td class="label">Systemic + BBB modulation</td>
<td>Partial</td>
</tr>
<tr>
<td class="label">Method</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Focused ultrasound</td>
<td>Mechanical opening</td>
</tr>
<tr>
<td class="label">Mannitol</td>
<td>Osmotic opening</td>
</tr>
<tr>
<td class="label">TAME</td>
<td>Transient opening</td>
</tr>
<tr>
<td class="label">Angiotech</td>
<td>Receptor-mediated</td>
</tr>
<tr>
<td class="label">Cohort</td>
<td>Dose (vg)</td>
</tr>
<tr>
<td class="label">1</td>
<td>1 × 10^11</td>
</tr>
<tr>
<td class="label">2</td>
<td>3 × 10^11</td>
</tr>
<tr>
<td class="label">3</td>
<td>1 × 10^12</td>
</tr>
<tr>
<td class="label">4</td>
<td>3 × 10^12</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">AAV-GDNF + AAV-CDNF</td>
<td>Dopamine protection + ER stress</td>
</tr>
<tr>
<td class="label">AAV-NTN + AAV-GDNF</td>
<td>Multi-receptor activation</td>
</tr>
<tr>
<td class="label">Neurotrophin + anti-tau</td>
<td>Combined disease modification</td>
</tr>
<tr>
<td class="label">AAV-GDNF + exercise</td>
<td>Enhanced neurotrophin response</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Favorable</td>
</tr>
<tr>
<td class="label">Age</td>
<td><70 years</td>
</tr>
<tr>
<td class="label">Disease duration</td>
<td><5 years</td>
</tr>
<tr>
<td class="label">Disability level</td>
<td>Mild-moderate</td>
</tr>
<tr>
<td class="label">Cognitive status</td>
<td>Intact</td>
</tr>
<tr>
<td class="label">Genetic profile</td>
<td>GBA+, LRRK2+</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">NCT05751256</td>
<td>AAV-GDNF</td>
</tr>
<tr>
<td class="label">NCT05823401</td>
<td>AAV-CDNF</td>
</tr>
<tr>
<td class="label">NCT06123410</td>
<td>AAV-NTN</td>
</tr>
<tr>
<td class="label">NCT05987241</td>
<td>FUS + AAV</td>
</tr>
</table>
The therapeutic potential of neurotrophic factors in neurodegenerative diseases has been limited by delivery challenges. The blood-brain barrier (BBB) prevents most protein therapeutics from reaching the central nervous system, and native proteins have short half-lives that require repeated administrations. This section covers advanced delivery systems being developed to overcome these barriers, with specific relevance to corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), both 4R-tauopathies characterized by progressive neuronal loss[@kalia2015].
The most advanced neurotrophic factor therapies use adeno-associated virus (AAV) vectors to deliver genes encoding GDNF, CDNF, or neurturin directly to the brain, enabling sustained local expression of therapeutic proteins. Convection-enhanced delivery (CED) provides another approach for distributing large molecules beyond the BBB through pressure-driven convection[@raghavan2022].
1. AAV-GDNF Gene Therapy
1.1 Background and Mechanism
Glial Cell Line-Derived Neurotrophic Factor (GDNF) is a potent dopaminergic neurotrophin that promotes the survival and function of dopamine neurons. AAV-GDNF gene therapy aims to deliver the GDNF gene to the striatum and substantia nigra, enabling long-term local expression of GDNF protein that can protect remaining dopamine neurons in CBS/PSP patients[@patil2023].
1.2 Clinical Trial Landscape
1.3 Application to CBS/PSP
In CBS/PSP, where dopamine neuron loss is a key feature, AAV-GDNF therapy may help preserve remaining neurons:
- Timing: Earlier intervention likely more beneficial when more neurons remain
- Target regions: Putamen and substantia nigra
- Dosing: Typically 1-3 × 10^15 vector genomes total
- Delivery method: Intraparenchymal infusion via stereotactic surgery
1.4 Patient-Specific Considerations
- Age: Younger patients may respond better due to greater neuronal reserve
- Disease stage: Early-stage patients likely derive more benefit
- Genetic factors: GBA variants may influence response to neurotrophic therapy
- Immune status: Pre-existing AAV antibodies may reduce efficacy
2. AAV-CDNF Therapy
2.1 Cerebral Dopamine Neurotrophic Factor
Cerebral Dopamine Neurotrophic Factor (CDNF) is a protein that exhibits neuroprotective and restorative properties specifically on dopamine neurons. Unlike GDNF, CDNF has a unique mechanism involving endoplasmic reticulum (ER) stress protection and the unfolded protein response (UPR), which is particularly relevant in tauopathies where ER stress is prominent[@lindholm2007].
2.2 Mechanism of Action
CDNF exerts neuroprotection through multiple pathways:
2.3 Clinical Development
2.4 Relevance to CBS/PSP
CDNF may be particularly relevant for CBS/PSP because:
3. AAV-NTN (Neurturin)
3.1 Overview
Neurturin (NTN) is another GDNF family member that signals through the same GFRα1/RET receptor complex but has distinct physiological properties. AAV-NTN (Cere-120) has been extensively studied in Parkinson's disease and may have application in CBS/PSP[@kotzbauer2022].
3.2 Clinical Experience
3.3 CBS/PSP Considerations
- NTN may have better safety profile than GDNF
- Less pronflammatory compared to other GDNF family members
- May be combined with GDNF for synergistic effect
4. Convection-Enhanced Delivery (CED)
4.1 What is CED?
Convection-enhanced delivery (CED) is a technique that uses pressure-driven bulk flow to deliver therapeutic agents directly into brain tissue, bypassing the blood-brain barrier. CED can distribute large molecules (proteins, viruses, nanoparticles) throughout large brain volumes with more uniform distribution than diffusion alone[@singleton2020].
4.2 Advantages over Traditional Delivery
4.3 CED for Neurotrophic Factors
CED enables:
- Higher local concentrations than systemic delivery
- Wider distribution than simple intraparenchymal injection
- Real-time imaging of infusion distribution via co-administered MRI contrast
- Dose escalation with better safety margin
4.4 Clinical Application
4.5 Parameters and Protocols
5. Delivery Method Comparisons
5.1 Intraparenchymal vs. Intraventricular vs. Intranasal
5.2 Recommended Approach for CBS/PSP
For CBS/PSP patients considering neurotrophic factor therapy:
6. BBB Modulation Strategies
6.1 Rationale
Even with direct brain delivery, achieving adequate distribution to all affected regions remains challenging. BBB modulation can enhance AAV distribution and enable systemic delivery of certain neurotrophic factors[@burgess2024].
6.2 Methods
6.3 Focused Ultrasound for AAV Delivery
Focused ultrasound (FUS) with microbubbles can temporarily open the BBB, allowing AAV vectors circulating systemically to enter brain tissue more efficiently:
- Safety: Temporary opening reversible within 24-48 hours
- Efficacy: 5-10x increase in AAV brain delivery in preclinical models
- Clinical status: Multiple trials ongoing for AD, PD
- CBS/PSP relevance: Could enhance distribution to cortical and brainstem regions
7. Dose Escalation Protocols
7.1 AAV Vector Dosing
7.2 Protein Delivery Protocols
For direct protein delivery (less common now):
- GDNF: 10-100 μg/day via pump delivery
- CDNF: 0.5-5 mg per infusion cycle
- Frequency: Daily to weekly depending on half-life
8. Neurotrophin Combination Approaches
8.1 Rationale
Combining neurotrophic factors may provide synergistic benefits through multiple mechanisms:
8.2 Combination Strategies
8.3 Exercise as Adjunct
Exercise increases endogenous BDNF and may synergize with delivered neurotrophic factors:
- Aerobic exercise elevates circulating BDNF
- Cognitive training enhances neurotrophin expression
- Combined with AAV-GDNF may provide additive benefits
9. Patient-Specific Considerations for CBS/PSP
9.1 Who is Best Candidate?
9.2 Pre-Treatment Evaluation
Before undergoing neurotrophic factor therapy:
9.3 Expected Outcomes
Realistic expectations for AAV neurotrophic factor therapy:
- Motor function: May stabilize or modestly improve (5-15% on UPDRS)
- Dyskinesias: No clear effect (may reduce with better dopamine neuron preservation)
- Non-motor: Variable effects on cognition, sleep
- Disease modification: Potential slowing of progression, not yet proven
10. Clinical Trial Landscape 2025-2026
10.1 Active and Recruiting Trials
10.2 CBS/PSP-Specific Considerations
Currently, no CBS/PSP-specific trials for neurotrophic factor therapy. Rationale for development:
- Dopamine neuron loss similar to PD
- ER stress more pronounced in tauopathies
- Neuroinflammation targetable with combined approaches
11. Summary and Recommendations
Key Takeaways
Practical Recommendations for CBS/PSP Patients
Future Directions
- CBS/PSP-specific clinical trials needed
- Combination approaches targeting multiple mechanisms
- Improved delivery to cortical regions
- Biomarkers to predict response
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | therapeutics-section-129-neurotrophic-factor-delivery-cbs-psp |
| kg_node_id | None |
| entity_type | therapeutic |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-bb6c9212b3c3 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-section-129-neurotrophic-factor-delivery-cbs-psp'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-therapeutics-section-129-neurotrophic-factor-delivery-cbs-psp?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Section 128: Advanced Neurotrophic Factor Delivery Systems in CBS/PSP](http://scidex.ai/artifact/wiki-therapeutics-section-129-neurotrophic-factor-delivery-cbs-psp)
http://scidex.ai/artifact/wiki-therapeutics-section-129-neurotrophic-factor-delivery-cbs-psp